ArticleWorld journal of gastrointestinal surgery2025
Efficacy of acupoint catgut embedding therapy for phlegm-turbidity and blood-stasis metabolic dysfunction-associated fatty liver disease.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo optimal treatment has been established for metabolic dysfunction-associated fatty liver disease with phlegm-turbidity and blood-stasis syndrome (MAFLD-PTBS), highlighting the need for more effective therapeutic approaches.
aimTo elucidate the clinical effectiveness of acupoint catgut embedding therapy (ACET) for MAFLD-PTBS and preliminarily examine its association with biomarkers, particularly platelet-derived growth factor (PDGF).
methodsWe retrospectively enrolled 80 patients with MAFLD-PTBS, divided into an ACET group (
resultsSignificant differences were observed both within group (pre-
conclusionACET exhibits promising clinical effectiveness for managing MAFLD-PTBS, with effects closely associated with serum concentrations of PDGF, TGF-β1, and CK-18.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.